Production (Stage)
CG Oncology, Inc.
CGON
$25.46
-$0.40-1.55%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 52.00K | 456.00K | 43.00K | 111.00K | 529.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 52.00K | 456.00K | 43.00K | 111.00K | 529.00K |
| Cost of Revenue | 27.47M | 26.80M | 19.62M | 18.47M | 17.21M |
| Gross Profit | -27.42M | -26.34M | -19.58M | -18.36M | -16.68M |
| SG&A Expenses | 14.79M | 11.71M | 8.72M | 7.49M | 5.79M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 42.26M | 38.51M | 28.34M | 25.96M | 23.00M |
| Operating Income | -42.20M | -38.05M | -28.30M | -25.85M | -22.47M |
| Income Before Tax | -34.45M | -31.80M | -20.41M | -18.90M | -16.93M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -34.45M | -31.80M | -20.41M | -18.90M | -16.93M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -34.45M | -31.80M | -20.41M | -18.90M | -16.93M |
| EBIT | -42.20M | -38.05M | -28.30M | -25.85M | -22.47M |
| EBITDA | -42.18M | -38.05M | -28.27M | -25.85M | -22.47M |
| EPS Basic | -0.45 | -0.46 | -0.30 | -0.28 | -0.36 |
| Normalized Basic EPS | -0.28 | -0.29 | -0.19 | -0.18 | -0.22 |
| EPS Diluted | -0.45 | -0.46 | -0.30 | -0.28 | -0.36 |
| Normalized Diluted EPS | -0.28 | -0.29 | -0.19 | -0.18 | -0.22 |
| Average Basic Shares Outstanding | 76.19M | 69.05M | 67.14M | 66.65M | 47.06M |
| Average Diluted Shares Outstanding | 76.19M | 69.05M | 67.14M | 66.65M | 47.06M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |